| Literature DB >> 26449843 |
Mellar Davis1,2,3, Pamela Gamier4,5,6.
Abstract
Constipation is common in the general population and for those on opioids and/or who are suffering from advanced cancer. Self-management consists of dietary changes, exercise, and laxatives. However, responses to self-management efforts are often inadequate to relieve the subjective and objective experience of constipation. Multiple new anti-constipating medications have recently been tested in randomized trials and the following are available commercially: probiotics, prucalopride, lubiprostone, linaclotide, elobixibat, antidepressants, methylnaltrexone, alvimopan, and naloxegol. This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation.Entities:
Keywords: Antagonist; Constipation; Linaclotide; Lubiprostone; Mu receptor; Probiotics; Prokinetics; Transporter
Mesh:
Substances:
Year: 2015 PMID: 26449843 DOI: 10.1007/s11912-015-0481-x
Source DB: PubMed Journal: Curr Oncol Rep ISSN: 1523-3790 Impact factor: 5.075